The role of moclobemide in endogenous depression: a survey of recent data.
Earlier studies demonstrated that moclobemide has good efficacy as an antidepressant. Its efficacy was comparable to reference antidepressants, both in endogenous and non-endogenous depression. A meta-analysis was performed of recent data from more than 2000 patients who had participated in double-blind trials with moclobemide and comparison drugs. Based on HAMD-17 baseline scores, the sample was divided into three groups according to the severity of depression. In all three, moclobemide was as effective as comparison drugs, both in endogenous and non-endogenous depression. The antidepressant efficacy of both moclobemide and reference drugs was more pronounced in endogenous than in non-endogenous depression, whatever the severity.